HF20 Set (system of replacement kidney therapy)

2020: The announcement of HF20 Set Baxter - the system of replacement kidney therapy

In the middle of August, 2020 the Baxter company announced release of the HF20 Set and ST Set systems intended for continuous replacement kidney therapy. Both products can be used with control blocks of Prismaflex or PrisMax.

In the conditions of emergency aid during COVID-19 pandemic the HF20 Set system can be used for treatment of patients with a low weight (8-20 kg) and low volume of blood who cannot be connected to an extracorporal circuit of large volume, and the ST Set system can be used in departments of emergency aid.

The HF20 Set system of Baxter company provides the low volume of an extracorporal circuit (58 ml) and includes the filtering membrane from a poliarilefirsulfon (PAES). In turn the ST Set system offers three sizes of circuits for different patients and AN69 membrane patented by Baxter for adsorption of toxins. The company stated that the limited initial batch of HF20 Set and ST Set will come to hospitals of the USA "in the shortest possible time", and significant increase in production is in the future planned.

Baxter provided the system of continuous replacement kidney therapy

Considering the permanent need for the systems of replacement kidney therapy, adding in our portfolio of HF20 Set and ST Set will allow hospitals to react to different needs of patients more flexibly, - the specialist in urgent therapy of Baxter Reaz Rasul claims. - We are glad that the HF20 Set system will help patients to receive with a low weight required replacement kidney therapy during COVID-19 pandemic.

It not the first emergency permission which regulatory bodies issue to the systems of replacement kidney therapy during a pandemic - so since April, 2020 the Baxter company uses the Oxiris filter during dialysis for simultaneous removal of tsitokin, endotoxins, liquid and uraemic toxins.^[1]

Notes